Patents Assigned to Amgen
  • BISPECIFIC OR BIPARATOPIC ANTIGEN BINDING PROTEINS AND USES THEREOF
    Publication number: 20230137351
    Abstract: The present invention relates to bispecific or biparatopic antigen binding proteins, polynucleotides encoding the same, and methods of making bispecific or biparatopic antigen binding proteins. Also described herein is a method to assemble IgG-like biparatopic or bispecific antibodies from VH only antigen binding proteins.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 4, 2023
    Applicant: AMGEN INC.
    Inventors: Wei YAN, Zhi LIU, Christopher MURAWSKY, Chadwick Terence KING, Yang LI, Zhonghua HU, Desiree LIM
  • Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases
    Patent number: 11639332
    Abstract: Provided herein are azo prodrugs of small-molecule isoindoline-1,3-diones and isoindoles anti-inflammatory inhibitors according to formula IA, in particular PDE4 inhibitors, which prodrugs can be administered orally to a subject in need thereof, whereby the prodrugs are cleaved in the colon and the PDE4 inhibitor released.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: May 2, 2023
    Assignees: AMGEN (EUROPE) GMBH
    Inventor: William R. Baker
  • PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
    Publication number: 20230128444
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: September 28, 2022
    Publication date: April 27, 2023
    Applicant: AMGEN INC.
    Inventors: Hailing HSU, Ming ZHANG, Gunasekaran KANNAN, Frederick W. JACOBSEN, Wayne H. TSUJI
  • MAMMALIAN CELL CULTURE
    Publication number: 20230129523
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.
    Type: Application
    Filed: December 20, 2022
    Publication date: April 27, 2023
    Applicant: AMGEN INC.
    Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
  • Prevention of adverse effects caused by CD3 specific binding domains
    Patent number: 11633408
    Abstract: The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: April 25, 2023
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Dirk Nagorsen, Juergen Scheele
  • Drug injection device with visual and audio indicators
    Patent number: 11633548
    Abstract: A drug injection device (10) including a housing (12) for holding a container (20) having a needle (24) for penetrating skin and a plunger (42) for expelling a drug stored in the container. The device includes visual and/or audible indicators for indicating that the correct depth of needle penetration has been achieved and that drug injection/extrusion has been started and/or completed. The device may further include a label (140) for visually confirming the quality of the drug contained therein. Alternatively, a tray (110) may be provided for receiving the drug injection device, which allows the quality of the drug contained therein to be visually confirmed.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: April 25, 2023
    Assignee: AMGEN INC.
    Inventors: Peter V. Shultz, Christopher R. Folk, Sigrid Moeslinger, Masamichi Udagawa, Molly Evans, Lin Gao, Lisa Nugent
  • Heterodimeric bispecific antibodies
    Patent number: 11634502
    Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 25, 2023
    Assignee: AMGEN INC.
    Inventors: Wei Yan, Martin J. Pentony, Luis G. Borges, Mark L. Michaels
  • Mammalian cell culture
    Patent number: 11634476
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: April 25, 2023
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • METHYLATION OF MCL-1 COMPOUNDS
    Publication number: 20230117777
    Abstract: Disclosed herein is an improved process for the synthesis of compound (A): (A), or a salt or solvate thereof via methylation of compound (B): (B), or a salt or solvate thereof, a crystalline hydrate of compound A, and pharmaceutical formulations comprising a crystalline hydrate of compound (A).
    Type: Application
    Filed: March 30, 2021
    Publication date: April 20, 2023
    Applicant: AMGEN INC.
    Inventors: Michal ACHMATOWICZ, Sheng CUI, Tsang-Lin HWANG, Neil Fred LANGILLE, Janine K. TOM, James E. HUCKLE, Markian STEC, Tian WU, Sean P. BROWN
  • COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
    Publication number: 20230121955
    Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: July 21, 2022
    Publication date: April 20, 2023
    Applicant: Amgen Inc.
    Inventors: James Russell LIPFORD, Jude Robert CANON, Anne Y. SAIKI, Karen Louise REX
  • MAMMALIAN CELL CULTURE
    Publication number: 20230117598
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Application
    Filed: December 14, 2022
    Publication date: April 20, 2023
    Applicant: AMGEN INC.
    Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
  • Drug delivery device with gear module and related method of assembly
    Patent number: 11617837
    Abstract: Drug delivery devices and related methods of assembly are disclosed. The drug delivery device may include a main housing having an interior surface defining an enclosed space, and an exterior surface releasably attachable to a patient. A container may be disposed in the enclosed space and include a reservoir containing a drug and a stopper. A drive assembly may also be disposed in the enclosed space and configured to move the stopper through the reservoir to expel the drug from the reservoir. The drive assembly may include a rotational power source and a gear module. The gear module may include a mounting plate and a plurality of gears rotatably connected to the mounting plate. Furthermore, the mounting plate may be separate from the main housing.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 4, 2023
    Assignee: AMGEN INC.
    Inventors: Jerome Olivas, Guojie Song, Sudeshna Dutta Ray
  • SMARCA2-VHL DEGRADERS
    Publication number: 20230091042
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: March 23, 2023
    Applicant: AMGEN INC.
    Inventors: Abhisek BANERJEE, Victor J. CEE, Ning CHEN, Xiaofen LI, Ryan Paul WURZ
  • Self-buffering antibody formulations
    Patent number: 11607451
    Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 21, 2023
    Assignee: Amgen Inc.
    Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, Jr., David Brems, Susan Irene Hershenson
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    Patent number: 11608344
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 21, 2023
    Assignees: AMGEN INC., VIGIL NEUROSCIENCE, INC.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
    Publication number: 20230078200
    Abstract: The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 16, 2023
    Applicant: AMGEN INC.
    Inventors: Bin WU, Michael OLLMANN, Oliver HOMANN, Yuan CHENG
  • Handheld drug delivery device
    Patent number: D985116
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: May 2, 2023
    Assignee: AMGEN INC.
    Inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Øhlenschlæger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle
  • Handheld drug delivery device
    Patent number: D985117
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: May 2, 2023
    Assignee: AMGEN INC.
    Inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Øhlenschlæger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle
  • Handheld drug delivery device
    Patent number: D985118
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: May 2, 2023
    Assignee: AMGEN INC.
    Inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Øhlenschlæger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle
  • Handheld drug delivery device
    Patent number: D985119
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: May 2, 2023
    Assignee: AMGEN INC.
    Inventors: Matias Melander, Bjarke Lykke Ludvig Svendsen, Christian Plambech, Michael Sorensen, Dylan Bourelle